

Democratizing CAR-T therapies for cancer patients globally

Company Profile

T-CURX is a German Biotech company, located in Würzburg and Munich, focused on developing innovative CAR-T therapies, based on non-viral, transposon-based CAR-T manufacturing. T-CURX' CAR-T therapies only require cost-effective and scalable mRNA and DNA vectors which are used (i) to develop an internal pipeline of innovative CAR-T therapies in hematology and solid tumors, (ii) to widely deploy this technology in the context of local, point-of-care and bed-side CAR-T manufacturing, and, optionally, (iii) for *in vivo* CAR-T generation with novel mRNA/DNA Lipo-Nano-Particles (LNPs). This strategy addresses the market need for cost-effective and scalable autologous CAR-T therapies. Due to complex and expensive virus-based manufacturing of FDA-approved CAR-T products (\$ 350-475K/product), only about 9'000 CAR-T products reached patients in 2023, mostly in G7 countries. T-CURX CAR-T solutions will democratize CAR-T therapies for cancer patients globally, incl. regions like LATAM, MENA and APAC, where CAR-T therapies are not available or affordable, but clearly in high demand.

Strong IP portfolio from a decade of CAR-T research

T-CURX has strong know-how in non-viral CAR-T manufacturing from a decade of CAR-T research in Prof. Michael Hudecek's lab, one of T-CURX co-founders. This know-how is protected by a strong IP portfolio, including 11 patent families protecting the T-CURX' CAR-T technologies and product candidates.

Strong CAR-T pipeline in hematology & solid tumors, 6-12 mo away from Ph1

T-CURX is preparing clinical trial applications (CTAs) for three differentiated CAR-T products, one in hematology (AML & CLL) and two programs against cross-entity targets present in blood cancers and solid tumors in collaboration with Prof. Hudecek's lab at Univ. Würzburg. All programs will go into Ph1 clinical trials in the next 6-12 months. The 5-year development plan for the clinical and the bedside CAR-T system with optional transposon-LNP technology is outlined below.

Strong Leadership and industry-experienced Board of Directors

T-CURX Leadership team and Board of Directors has a strong Biotech/Pharma track record in building and successfully exiting Biotech companies. T-CURX team is led by Ulf Grawunder as CEO (previously 4-Antibody & NBE-Therapeutics) and Marion Jung as COO (previously ChromoTek). Clinical development activities are guided by T-CURX' co-founder and clinical expert, Michael Hudecek, as CMO.

Financials

So far, T-CURX has raised € 5 Mio Seed Financing from European/US Family Offices in addition to € 1.5 Mio non-dilutive grant funding. T-CURX aims to raise € 25 M Series A financing to advance its clinical CAR-T program in AML & CLL and to develop a bedside CAR-T system with optionally transposon-LNPs for *in vivo* CAR-T applications in the next 3 years. Two CAR-T programs in collaboration with the University of Würzburg are funded by a € 8.7 Mio NCT grant (for BCL & solid tumors) and a € 6.5 Mio BMBF grant (for MM & RCC) until end of Ph2a, which can then be fully transferred to T-CURX. A € 35 Mio Series B financing in 2028 shall position the company in 4-5 years for an exit with 3 clinical CAR-T programs (2 programs taken over after Ph2a) and a scalable and cost-effective CAR-T bedside manufacturing system ready for deployment in the clinic.



	2025				2026				2027				2028				2029			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
AML & CLL program	CTA-Preps				Phase 1 clinical trial				Phase 2a clinical trial				pivotal Phase 2b							
BCL & solid tumor program	Site act.				Phase 1 clinical trial				Phase 2a clinical trial				pivotal Phase 2b							
MM & RCC program	CTA-Preps				Phase 1 clinical trial				Phase 2a clinical trial				pivotal Ph 2b							
Development bedside CAR-T	Development Bedside CAR-T				Optimization Bedside				CTA-Preps				Clinical validation of Bedside CAR-T system							

AML: Acute Myeloid Leukemia, CLL: Chronic Lymphocytic Leukemia, BCL: B cell lymphopoma, MM: Multiple Myeloma, RCC: Renal Cell Carcinoma

■ BMBF and NCT-grant funded activities ■ T-CURX funded activities

Management

Ulf Grawunder, PhD, CEO & Co-Founder
Michael Hudecek, MD, Co-Founder & CMO
Marion Jung, PhD, COO
Jan Van den Brulle, PhD, VP R&D
Caroline Burger, PhD, Global Head BD
Christian Söllner, General Counsel

Independent Board members

Hanspeter Gerber, PhD (US) (Chairman)
Berd Eschgfäller, PhD (CH)

Scientific Advisory Board

Michael Hudecek, Prof., MD, Co-Founder (D)
Christoph Rader, Prof., PhD, Co-Founder (US)
Hermann Einsele, Prof., MD (D)
Cameron Turtle, Prof., MD, PhD (AU)

CAR-T specialists

Sabrina Friedel, PhD
Thomas Nerreter, PhD
Vasco Goncalves, PhD

Company at a glance

- T-CURX team with strong track record in CAR-T research & Biotech industry
- Sleeping Beauty transposon-based, virus-free gene transfer offers unparalleled scalability and efficiency
- In combination with compact devices T-CURX scalable CAR-T technology can be deployed in point-of-care and bedside manufacturing settings globally
- IP portfolio (Technology & Pipeline) of 11 patent families exclusive to T-CURX
- CAR-T program in AML & CLL is ready for clinical trial application (in 2025)
- Two additional CAR-T programs funded by € 15 M research grants will go into Ph1 trials in collaboration with Univ. Würzburg

T-CURX GmbH

Innovation and Founder Centre (IGZ)
 Friedrich-Bergius-Ring 15
 97076 Würzburg, Germany

Innovation Center Biotechnology (IZB)
 Am Klopferspitz 19
 82152 Martinsried, Germany

P: +49-(0)-931-250-99-712
 E: info@t-curx.com
 W: www.t-curx.com

